Alumis reports new Phase 3 data for envudeucitinib in psoriasis
Alumis said new Phase 3 data show envudeucitinib rapidly and durably improved psoriasis burden across scalp, itch, and quality-of-life measures, building on ONWARD3 Week 48 results.
Story updates
08:01:35 AM UTC
SquawkNews
Alumis reported new ONWARD Phase 3 data showing envudeucitinib improved scalp disease, itch, and QoL, with ONWARD3 showing 54% PASI 100 at Week 48. The company remains on track to submit an NDA for moderate-to-severe plaque psoriasis in 4Q 2026.Material DetailsContext by AI AnalystThis is late-stag…